MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on January 3, 2006; DOI: 10.1124/mol.105.018408


0026-895X/06/6904-1125-1136$20.00
Mol Pharmacol 69:1125-1136, 2006

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.018408v1
69/4/1125    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shacka, J. J.
Right arrow Articles by Roth, K. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shacka, J. J.
Right arrow Articles by Roth, K. A.
Original Article

Bafilomycin A1 Inhibits Chloroquine-Induced Death of Cerebellar Granule Neurons

John J. Shacka, Barbara J. Klocke, Masahiro Shibata, Yasuo Uchiyama, Geeta Datta, Robert E. Schmidt, and Kevin A. Roth

Department of Pathology, Division of Neuropathology (J.J.S., B.J.K., K.A.R.) and Department of Medicine (G.D.), University of Alabama at Birmingham, Birmingham, Alabama; Department of Cell Biology and Neurosciences, Osaka University Graduate School of Medicine, Osaka, Japan (M.S., Y.U.); and Department of Pathology and Immunology, Division of Neuropathology, Washington University School of Medicine, St. Louis, Missouri (R.E.S.)

Received August 23, 2005; accepted January 3, 2006

Abstract

Treatment of cells with the macrolide antibiotic bafilomycin A1, an inhibitor of vacuolar (V)-ATPase, or with the lysosomotropic agent chloroquine, has been shown to pharmacologically inhibit autophagy as evidenced by an accumulation of autophagosomes, which in turn causes Bax-dependent apoptosis. However, bafilomycin A1 has also been reported to inhibit chloroquine-induced apoptosis, suggesting a complex interrelationship between these two inhibitors of autophagy. To determine whether the cytoprotective effect of bafilomycin A1 on chloroquine-treated cells was dependent on inhibition of V-ATPase, we examined the single and combined effects of bafilomycin and chloroquine on cultured cerebellar granule neurons. When added separately, chloroquine or high concentrations of bafilomycin A1 (≥10 nM) induced a dose-dependent inhibition of autophagy (as measured by an increase in LC3-II, a marker specific for autophagosomes), followed by caspase-3 activation and cell death. When added in combination, bafilomycin A1 potently inhibited chloroquine-induced caspase-3 activity and cell death at concentrations (≤1 nM) that neither altered vacuolar acidification nor inhibited autophagy. The neuroprotective effects of bafilomycin A1 against chloroquine were substantially greater than those produced by Bax deficiency. Bafilomycin A1-induced neuroprotection seemed to be stimulus-specific, in that staurosporine-induced death was not attenuated by coaddition of bafilomycin A1. Together, these data suggest that in addition to promoting death via inhibition of V-ATPase and autophagy, bafilomycin A1 possesses novel, neuroprotective properties that inhibit Bax-dependent activation of the intrinsic apoptotic pathway resulting from the pharmacological inhibition of autophagy.


Cell death is classified by morphological criteria into distinct categories, including type I apoptotic death and type II autophagic death (Schweichel and Merker, 1973Go; Clarke, 1990Go). Apoptosis is triggered by activation of either extrinsic (death receptor-mediated) or intrinsic (mitochondrial-associated) death pathways (Bredesen, 2000Go; Putcha et al., 2002Go). Both apoptotic pathways are regulated by pro- and antiapoptotic members of the Bcl-2 family (Shacka and Roth, 2005Go) and culminate in the activation of effector caspases, which induce the nuclear condensation, DNA fragmentation, and cell shrinkage that define apoptotic morphology (Schweichel and Merker, 1973Go; Clarke, 1990Go). Autophagy is a homeostatically regulated pathway whereby autophagosomes fuse with lysosomes for the subsequent degradation and recycling of macronutrients and damaged organelles by lysosomal enzymes (Klionsky and Emr, 2000Go; Eskelinen, 2005Go; Lum et al., 2005bGo). Autophagosomes are defined ultrastructurally as intracellular, double-membraned vesicles encompassing organelles and cytoplasm and biochemically by accumulation of microtubule-associated protein light chain 3-II (LC3-II). LC3 is a microtubule-associated protein that upon processing from its cytoplasmic form (LC3-I) inserts via covalent lipidation into the inner and outer limiting membranes of autophagosomes as LC3-II (Ichimura et al., 2000Go; Kabeya et al., 2000Go). Under conditions of limited trophic support, cells induce autophagy as a catabolic means of survival by increasing the turnover of its intracellular components (Lum et al., 2005aGo). If trophic support remains low, progressive cellular atrophy may lead to autophagic cell death that is defined morphologically by increased numbers of autophagosomes in a degenerating cell and may be concomitant with apoptotic morphology.

Chloroquine, a widely-prescribed antimalarial agent, is also indicated for treatment of autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis (Lai et al., 2001Go; Issa and Ruderman, 2004Go; Baird, 2005Go; Wozniacka and McCauliffe, 2005Go). As a weak base, chloroquine concentrates in acidic vesicles such as lysosomes and raises their pH, an effect that has been shown to disrupt the function of lysosomal enzymes (de Duve et al., 1974Go; Seglen and Gordon, 1980Go). Chloroquine-induced death has been described in many cell types including immature neurons (Zaidi et al., 2001Go) and HeLa cells (Boya et al., 2003Go, 2005Go) and has been shown to be regulated by members of the Bcl-2 family. Previous studies have indicated that chloroquine induces a transient increase in staining of acidic vesicles with LysoTracker Red, an effect that precedes a disruption in mitochondrial membrane potential and cell death (Boya et al., 2003Go, 2005Go). Bafilomycin A1 is a macrolide antibiotic that was characterized initially for its selective inhibition of the vacuolar-type ATPase (V-ATPase) (Bowman et al., 1988Go; Drose et al., 1993Go). At nanomolar concentrations, bafilomycin A1 disrupts the vesicular proton gradient and ultimately increases the pH of acidic vesicles (Yoshimori et al., 1991Go). This disruption of vesicular acidification by both bafilomycin A1 and chloroquine has been proposed to prevent the fusion of autophagosomes with lysosomes (Yamamoto et al., 1998Go; Boya et al., 2005Go), resulting in an inhibition of autophagy (Boya et al., 2005Go). It is noteworthy that this inhibition of autophagy has been shown to precede the disruption of mitochondrial membrane potential and Bax/Bak-dependent apoptosis (Boya et al., 2005Go), thus underscoring an important link between these two death processes.

Pretreatment of HeLa cells with a high concentration of bafilomycin A1 (100 nM) inhibits chloroquine-induced apoptosis (Boya et al., 2003Go). This protective effect of bafilomycin A1 was attributed to its ability to inhibit the initial localization of chloroquine to acidic vesicles, thereby blocking its disruption of both lysosomal function and the subsequent decrease in mitochondrial membrane potential and induction of apoptosis (Boya et al., 2003Go). It is noteworthy that this high concentration of bafilomycin A1 is known to inhibit V-ATPase completely (Bowman et al., 1988Go), induce vacuolar deacidification (Yoshimori et al., 1991Go; Boya et al., 2003Go, 2005Go), and promote apoptosis (Nishihara et al., 1995Go; Kinoshita et al., 1996Go; Kanzawa et al., 2003Go, 2004Go; Boya et al., 2005Go). These previous results led us to investigate whether bafilomycin A1 could also prevent the chloroquine-induced death of neuronal cells. In addition, we set out to determine whether bafilomycin A1 had any protective effects at concentrations below its reported ability to inhibit vesicular acidification. Results of the present study indicate a dramatic, bafilomycin A1-dependent reduction in chloroquine-induced apoptosis of cerebellar granule neurons (CGNs) by a mechanism that is independent of its effects on vacuolar acidification and is downstream of autophagosome formation.

Materials and Methods

Reagents. Unless otherwise noted, reagents were acquired from Sigma (St. Louis, MO).

Animals. C57BL/6J mice were used in all experiments. The generation of mice deficient in bax and caspase-3 has been described previously (Knudson et al., 1995Go; Kuida et al., 1996Go; Shindler et al., 1997Go). Genetic status was determined by polymerase chain reaction analysis of tail DNA extracts as described previously (Kuida et al., 1996Go; Shindler et al., 1997Go). Mice were cared for in accordance with the guidelines of the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All animal protocols were approved by the Institutional Animal Care and Use Committee of the University of Alabama at Birmingham.

Cell Culture. CGNs were isolated from postnatal day 7 mice as described previously (Nowoslawski et al., 2005Go). CGNs were plated in poly-L-lysine coated plates at a density of 1250 cells/mm2. Forty-eight well plates were used for viability and caspase activity assays; 100-mm dishes were used for Western blot analysis; four-well Permanox chamber slides (Nalgene; Nalge Nunc International, Naperville, IL) were used for analysis of vacuolar acidification; four-well glass chamber slides (Nalgene) were used for ultrastructural analysis; and six-well plates were used for protein degradation assays. CGNs were treated on in vitro day 4. The conditioned media was replaced with fresh media with or without chloroquine (5–40 µM final) in the presence or absence of bafilomycin A1 (final concentration, 0.1–100 nM), BOC-aspartyl(OMe)-fluoromethyl ketone (final concentration, 150 µM; MP Biomedicals, Aurora, OH), or cycloheximide (final concentration, 0.01–1 µg/ml). Separate cultures of CGNs were also treated for 24 h with staurosporine (0.1 µM), in the presence or absence of bafilomycin A1 (1–10 nM final).

Measurement of Viability and Caspase-3-Like Activity. Cell viability (via Calcein AM fluorogenic conversion assay; Molecular Probes, Eugene, OR) and caspase-3-like activity (via fluorogenic DEVD cleavage assay) were performed as described previously (Nowoslawski et al., 2005Go) and were expressed relative to untreated controls.

Labeling of CGNs with LysoTracker Red. Conditioned media was removed from CGNs grown in four-well, Permanox chamber slides. LysoTracker Red (0.05 µM; Molecular Probes, Eugene, OR) and Calcein AM (2.5 µg/ml; Molecular Probes) were prepared in Locke's buffer and added to each well for 30 min at 37°C. After this incubation, the cells were washed with Locke's buffer and coverslipped. Images were captured using a Carl Zeiss Axioskop microscope equipped with epifluorescence.

Ultrastructural Analysis of CGNs. After 24-h treatment with chloroquine and/or various concentrations of bafilomycin A1 that began on day 4 in vitro, cells were fixed overnight at 4°C with 3% glutaraldehyde in 0.1 M sodium phosphate buffer, pH 7.4, containing 0.45 mM Ca2+, rinsed three times with ice-cold buffer at 4°C, and osmicated (2% OsO4 in PBS; Electron Microscopic Sciences, Fort Washington, PA). Subsequently, wells were rinsed three times in deionized H2O and dehydrated in graded alcohols (30–100%). Cultures were treated overnight with a 1:1 mixture of 100% EtOH and Polybed (Polysciences, Warrington, PA). The 1:1 Polybed/EtOH mixture was replaced with complete Polybed and placed under vacuum for 4 h, then replaced by fresh complete Polybed and baked overnight in a 60°C oven under vacuum. Ultrathin sections were prepared with an ultramicrotome, collected onto slot grids, stained with uranyl acetate and lead citrate, and viewed with a JEOL 1200 transmission electron microscope.

Measurement of Degradation of Long-Lived Proteins. Measurement of long-lived protein degradation was performed with minor modifications as described previously (Pattingre et al., 2004Go). CGNs were radiolabeled on day 3 in vitro with 0.2 µCi/ml L-[14C]valine for 24 h at 37°C in valine-free neurobasal media (UCSF Cell Culture Core Facility, San Francisco, CA) and B-27 supplement (Invitrogen, Carlsbad, CA). After the radiolabeling period, unincorporated radioisotope was removed by three rinses with PBS, pH 7.4. Cells were then incubated with culture media containing 10 mM valine for 16 h at 37°C followed by three rinses with PBS to remove the radioactivity due to the degradation of short-lived proteins. Cells were then treated for 24 h at 37°C with chloroquine and/or bafilomycin A1 in media containing 10 mM valine. Cells and radiolabeled proteins from the media were then precipitated in ice-cold trichloroacetic acid [final concentration, 10% (v/v)]. The precipitated proteins were separated from the soluble radioactivity by centrifugation at 600g for 20 min and then dissolved in 0.2 N NaOH. Radioactivity was determined by liquid scintillation counting. Protein degradation was calculated by dividing the acid-soluble radioactivity recovered from media by the total radioactivity from the acid-soluble and precipitated fractions of cells and media and was expressed as percentage degradation per hour of treatment.

Western Blot. Cells were detached from their substrate by incubation for 5 min at 37°C with Accutase (Innovative Cell Technologies, San Diego, CA). Conditioned media and cells were centrifuged (700g, 5 min, 4°C). The supernatant was aspirated and re-suspended with 1 ml of ice-cold PBS, then centrifuged again (700g, 5 min, 4°C). The resultant pellet was resuspended in lysis buffer containing 25 mM HEPES, 5 mM EDTA, 5 mM MgCl2, 1% SDS, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 1% protease inhibitor cocktail, and 1% phosphatase inhibitor cocktail (Sigma). Cell lysates were sonicated to shear DNA and then centrifuged (10,000 rpm, 10 min, 4°C), and the resultant supernatant (cleared whole-cell lysates) was transferred to a fresh tube. Protein levels were determined subsequently via BCA assay (Pierce). Equal amounts of protein were resolved via SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride. After transfer, blots were cut in half at approximately 37 kDa. The lower molecular mass blots were used initially for the detection of active caspase-3 with an antibody raised against the cleaved or active fragment (Cell Signaling), and the upper molecular mass blots were used for detection of beta-III tubulin (Santa Cruz Biotechnology, Santa Cruz, CA) to normalize for protein loading. Blots were blocked for 1 h at room temperature in 5% milk, followed by overnight incubation with primary antibody. Blots were washed with 1x TBS containing 0.1% Tween 20, then incubated with secondary antibody (goat anti-rabbit IgG; Bio-Rad, Hercules, CA) for 1 h at room temperature and subsequently washed. Signal was detected using Supersignal chemiluminescence (Pierce). After detection of cleaved caspase-3, the bottom blot was stripped using Restore Western Blot stripping buffer (Pierce Chemical, Rockford, IL) then probed with rabbit anti-LC3 (provided by Uchiyama laboratory), using the same Western blot protocol as described above. Blots were scanned for densitometric analysis using Bio-Rad Quantity One software.

Statistics. Significant effects of treatment were analyzed either by one-factor ANOVA (if three or more groups) or by unpaired, two-tailed t test (if two groups). Genotype-specific effects of treatment were analyzed for significance via two-factor ANOVA. Post hoc analysis was conducted using Bonferroni's test. A level of p < 0.05 was considered significant.

Results

CGNs were treated with 5 to 40 µM chloroquine after 4 days in vitro and their viability and fractional caspase-3-like activity were measured 16 to 24 h later (Fig. 1, a and b). Chloroquine produced a concentration-dependent decrease in viability (Fig. 1a) and increase in caspase-3-like activity, with significant effects observed at concentrations of chloroquine ≥10 µM. Chloroquine decreased viability to 24% at 20 µM and to 8% at 40 µM (Fig. 1a), whereas a 6- to 7-fold increase in caspase-3-like activity was maximal at 20 to 40 µM (Fig. 1b). For all subsequent experiments, a concentration of 20 µM chloroquine was used. Treatment with the protein synthesis inhibitor cycloheximide (0.1–1 mg/ml) did not alter the magnitude of death induced by chloroquine (data not shown), which suggests that the deleterious effects of chloroquine were not dependent on de novo protein synthesis.


Figure 1
View larger version (10K):
[in this window]
[in a new window]
 
Fig. 1. Chloroquine decreases cell viability and increases caspase-3-like activity. Viability (a) expressed as percentage control (CTL) and fractional caspase-3-like activity (b) measured 24 h after treatment with chloroquine (5–40 µM). Viability (c) and caspase-3-like activity (d) were also measured for up to 48 h after treatment with 20 µM chloroquine. Three independent experiments of at least three replicates represent each time point and concentration tested. Significant effects of treatment and time were assessed via one-factor ANOVA with Bonferroni's post hoc test. For a and b, p < 0.05 (a, compared with CTL; b, compared with 5 µM chloroquine; c, compared with 10 µM chloroquine; d, compared with 20 µM chloroquine). For c and d, p < 0.05 (a, compared with 0 h; b, compared with 8 h; c, compared with 16 h; d, compared with 24 h).

 
Time course studies were performed to determine the temporal induction of caspase-3-like activity and cell death by chloroquine (Fig. 1, c and d). Viability decreased slightly (by 7%) but significantly after 8 h and continued to decrease significantly over the next 40 h (Fig. 1c). Caspase-3-like activity increased significantly 8 h after treatment with chloroquine and was maximal at 16 h (6-fold induction) and remained at high levels from 24 to 48 h (Fig. 1d). The temporal pattern of cleaved or "active" caspase-3 was confirmed by Western blot analysis (Fig. 2, a and b), which was evident at low levels by 8 h and was most robust at 16 h after treatment with chloroquine.


Figure 2
View larger version (33K):
[in this window]
[in a new window]
 
Fig. 2. Chloroquine induces biochemical markers of apoptosis and autophagy. Representative Western blot (a) measures cleaved caspase-3 and processing of LC3 in nontreated (NT) samples at 0 h and in control (CTL) or chloroquine (20 µM; CQ)-treated lysates from 4 to 48 h. At least three independent experiments were used to assess levels cleaved caspase-3 (b), LC3-I (c), and LC3-II (d), expressed relative to levels of beta-III-tubulin, and the ratio of LC3-II/I (e).

 

To determine the effects of chloroquine on autophagosomes, the processing of LC3 was assessed via Western blot (Fig. 2, a and c–e). Levels of the 18-kDa LC3-I seemed lower 24 to 48 h after treatment with chloroquine compared with control levels at those times (Fig. 2, a and b). LC3-II, the 16 kDa form of LC3 specific for membranes of autophagosomes (Kabeya et al., 2000Go), was elevated within 4 h after chloroquine addition and remained high through 48 h (Fig. 2, a and c). This increase in LC3-II was also reflected by an increase in the ratio of autophagosome-bound LC3-II to that of cytosolic LC3-I (Fig. 2d).

The effects of bafilomycin A1 on the survival and apoptosis of CGNs were assessed after 24 h (Fig. 3). By itself, bafilomycin A1 did not decrease viability or induce caspase-3-like activity at concentrations ≤1 nM but did so at concentrations ≥10 nM (Fig. 3, a and b). Western blot analysis was performed to confirm the effects of bafilomycin A1 on the activity of caspase-3 and to determine its effects on the processing of LC3 (Fig. 4). An increase in cleaved caspase-3 was only apparent upon treatment with 10 nM bafilomycin A1 (Fig. 4, a and b). Treatment with bafilomycin A1 at any concentration did not change levels of LC3-I, but 10 nM bafilomycin A1 induced a dramatic increase in levels of LC3-II (Fig. 4, a and c), which was also reflected by a dramatic increase in the ratio of LC3-II/LC3-I (Fig. 4d).


Figure 3
View larger version (15K):
[in this window]
[in a new window]
 
Fig. 3. Bafilomycin A1 (BafA1) concentration-dependently decreases viability and increases caspase-3-like activity. Viability (a) and fractional caspase-3-like activity (b) were measured 24 h after the addition of BafA1 (0.1–100 nM). Three independent experiments of at least three replicates represent each time point and concentration tested. Significant effects of treatment were assessed via one-factor ANOVA with Bonferroni's post hoc test; p < 0.05 (*, compared with 0, 0.1, and 0.3 nM BafA1; {dagger}, compared with 10 nM BafA1).

 

Figure 4
View larger version (22K):
[in this window]
[in a new window]
 
Fig. 4. Bafilomyicin A1 (BafA1) concentration-dependently increases markers of apoptosis and autophagy. Representative Western blot (a) measures cleaved caspase-3 and processing of LC3 in lysates after 24-h addition of BafA1. At least three independent experiments were used to assess levels of cleaved caspase-3 (b), LC3-I, and LC3-II (c) expressed relative to levels of beta-III-tubulin, and the ratio of LC3-II/LC3-I (d).

 
The effects of bafilomycin A1 were also assessed in the presence of a toxic dose of chloroquine (Fig. 5). Bafilomycin A1 significantly attenuated the chloroquine-induced decrease in viability at all concentrations tested and was maximal at 1 nM (viability of 88% with bafilomycin A1 versus 24% without; Fig. 5a). Although concentrations of 10 to 100 nM bafilomycin A1 by themselves decreased viability (Fig. 3a), they significantly attenuated the still larger decrease in viability induced by chloroquine (Fig. 5a). The chloroquine-induced increase in caspase-3-like activity was reduced only upon the coaddition of 0.3 to 1 nM bafilomycin A1, and was maximal at 1 nM (3-fold reduction; Fig. 5b).


Figure 5
View larger version (17K):
[in this window]
[in a new window]
 
Fig. 5. Bafilomycin A1 (BafA1) concentration-dependently attenuates chloroquine-induced decrease in viability and increase in caspase-3-like activity. Viability (a) and fractional caspase-3-like activity (b) were measured 24 h after the coaddition of 20 µM chloroquine (CQ) and BafA1. BafA1 did not prevent the decrease in viability after 24-h treatment with 0.1 µM STS (c). Three independent experiments of at least three replicates represent each concentration tested. For a and b, significant effects of BafA1 (in the presence or absence of CQ) were assessed via one-factor ANOVA with Bonferroni's post hoc test; p < 0.05 (a, compared with CTL; b, compared with CQ; c, compared with 0.1 nM BafA1; d, compared with 0.3 nM BafA1; e, compared with 1 nM BafA1). For c, significant effects of staurosporine (in the presence or absence of BafA1) were assessed via two-factor ANOVA and concentration-dependent differences of BafA1 were assessed via one-factor ANOVA with Bonferroni's post hoc test; p < 0.05 (a, compared with each concentration of BafA1 without staurosporine; b, compared with 0 and 1 nM BafA1).

 
To determine whether bafilomycin A1 affected the toxicity of a classic apoptosis-inducing stimulus, CGNs were treated for 24 h with 0.1 µM staurosporine (Fig. 5c), a concentration of this broad spectrum kinase inhibitor that significantly increases caspase-3-like activity and apoptosis in our culture system (data not shown). Treatment with staurosporine for 24 h significantly reduced viability to an average of 44%, an effect that was not altered by coadministration with 1 nM bafilomycin A1. Treatment with 10 nM bafilomycin A1, rather than protecting CGNs from staurosporine-induced death, further decreased the viability of staurosporine-treated CGNs to 20%.

Western blot analysis was performed to confirm the effects of bafilomycin A1 on the activity of caspase-3 and to determine its effects on the processing of LC3 in the presence of chloroquine (Fig. 6). The chloroquine-induced increase in cleaved caspase-3 was attenuated by cotreatment with ≤1 nM bafilomycin A1 (Fig. 6, a and b). Bafilomycin A1 did not attenuate chloroquine-induced levels of LC3-II but seemed to increase levels of LC3-I, which is reflected by a reduction in the ratio of LC3-II to LC3-I at all concentrations of bafilomycin A1 tested (Fig. 6, a and c).


Figure 6
View larger version (27K):
[in this window]
[in a new window]
 
Fig. 6. Bafilomycin A1 (BafA1) dose-dependently attenuates chloroquine-induced cleavage of caspase-3 and the ratio of LC3-II/LC3-I. Representative Western blot (a) indicates cleaved caspase-3 and processing of LC3 in samples treated for 24 h with BafA1 (0.3–10 nM) in the presence or absence of 20 µM chloroquine (CQ). At least three independent experiments were used to assess levels of cleaved caspase-3 (b), LC3-I, and LC3-II (c) expressed relative to levels of beta-III-tubulin, and the ratio of LC3-II to LC3-I (d).

 

Vacuolar acidification was measured after 24-h treatment with chloroquine and/or bafilomycin A1 by incubation with LysoTracker Red, in the presence of the viability marker calcein AM (Fig. 7). By itself, 1 nM bafilomycin A1 did not alter the staining pattern of LysoTracker Red or reduce viability compared with control cells (Fig. 7, a and b). In contrast, treatment with 10 nM bafilomycin A1 not only prevented any detection of vacuolar acidification by LysoTracker Red but also decreased numbers of viable CGNs (Fig. 7c), an effect that was similar in the presence or absence of chloroquine (Fig. 7, c and f). Treatment with chloroquine decreased numbers of viable CGNs (Fig. 7d). However, the population of CGNs that survived 24-h treatment with chloroquine exhibited a greater intensity of LysoTracker Red staining than that observed in control cells (Fig. 7d). The coaddition of 1 nM bafilomycin A1 and chloroquine (Fig. 7e) increased numbers of viable neurons that also exhibited a concomitant increase in LysoTracker Red staining intensity, compared with treatment with chloroquine or 1 nM bafilomycin A1 alone.


Figure 7
View larger version (28K):
[in this window]
[in a new window]
 
Fig. 7. Effects of chloroquine (CQ) and bafilomycin A1 (BafA1) on the labeling of acidic vesicles. CGNs were treated for 24 h (a, CTL; b, 1 nM BafA1; c, 10 nM BafA1; d, 20 µM CQ; e, CQ + 1 nM BafA1; f, CQ + 10 nM BafA1) and were subsequently labeled for acidic vesicles using Lysotracker Red and for viability using Calcein AM. Each experiment was repeated three times with similar results. Scale bar, 100 µm.

 
Electron microscopy was performed on CGNs to determine the effects of 24-h treatment with chloroquine with or without bafilomycin A1 on ultrastructural morphology. There were no morphological differences between control CGNs (Fig. 8a) and cells treated with 0.3 nM bafilomycin A1 (Fig. 8b). Treatment with 10 nM bafilomycin A1 (Fig. 8c) induced the accumulation of large, swollen, single-membraned vacuoles in the cytoplasm with electron-dense deposits, in addition to apoptotic nuclei. Chloroquine (Fig. 8, d and g) induced the formation of apoptotic nuclei and also the accumulation of single membraned vacuoles with dense, electron-dense deposits and a whorled appearance, possibly indicating mature, degradative autophagosomes or autophagolysosomes (Eskelinen, 2005Go). The vacuoles that accumulated upon treatment with 10 nM bafilomycin A1 (Fig. 8c) were much larger and swollen than those that accumulated upon treatment with chloroquine and were not whorled in appearance, which may indicate a population of mature autophagosomes whose fusion with lysosomes was blocked, as suggested previously (Yamamoto et al., 1998Go). Cotreatment with chloroquine and 0.3 nM bafilomycin A1 (Fig. 8, e and h) attenuated the chloroquine-induced appearance of apoptotic nuclei but did not prevent the accumulation of single membraned, whorled vacuoles with electron-dense deposits. Cotreatment with chloroquine and 10 nM bafilomycin A1 (Fig. 8, f and i) induced the accumulation of large, swollen, single-membraned vacuoles in addition to apoptotic nuclei.


Figure 8
View larger version (174K):
[in this window]
[in a new window]
 
Fig. 8. Effects of chloroquine (CQ) and bafilomycin A1 (BafA1) on morphology of CGNs as assessed ultrastructurally by electron microscopy (EM). CGNs were treated for 24 h (a, CTL; b, 0.3 nM BafA1; c, 10 nM BafA1; d, 20 µM CQ; e, CQ + 0.3 nM BafA1; f, CQ + 10 nM BafA1) and were subsequently processed for EM. Boxes in d–f refer to enlarged images of vacuoles represented in g–i, respectively. Arrows point to apoptotic nuclei. Arrowheads point to vacuoles with electron dense granules and whorled appearance. Asterisks indicate large, swollen vacuoles with electron dense granules. Scale bar, 2 µm for a–f and 0.5 µm for g–i.

 

Treatment with chloroquine has been shown previously to inhibit macroautophagy by inhibiting the degradation of long-lived proteins (Boya et al., 2005Go). In the present study, degradation of long-lived proteins was measured after 24-h treatment with chloroquine and/or bafilomycin A1 to determine whether chloroquine had similar effects on macroautophagy in CGNs, and whether bafilomycin A1 differentially affected macroautophagy in the presence or absence of chloroquine (Fig. 9). Chloroquine significantly inhibited the degradation of long-lived proteins versus control cultures, an effect that was not altered by cotreatment with either 1 or 10 nM bafilomycin A1. One nanomolar bafilomycin A1 by itself did not alter the degradation of long-lived proteins versus control. Although 10 nM bafilomycin A1 seemed to decrease the degradation of long-lived proteins compared with control, this effect did not reach statistical significance.


Figure 9
View larger version (18K):
[in this window]
[in a new window]
 
Fig. 9. Bafilomycin A1 (BafA1) does not attenuate chloroquine (CQ)-induced inhibition of macroautophagy. CGNs radiolabeled with 14C valine were treated with CQ, BafA1, or CQ+BafA1 for 24 h and processed subsequently for degradation of long-lived proteins. Data represent mean ± S.E.M. of three independent experiments and are expressed as percentage degradation per hour of treatment. Significant effects of treatment were assessed via one-factor ANOVA with Bonferroni's post hoc test; p < 0.05 (*, compared with CTL-treated cultures).

 
Cultures were prepared from Bax-deficient mice to determine the role of this pro-apoptotic member of the Bcl-2 family in chloroquine-induced death (Fig. 10). The targeted deletion of Bax significantly attenuated the chloroquine-induced decrease in viability (Fig. 10a) and increase in caspase-3-like activity (Fig. 10b), measured at 16 to 24 h, but did not provide any greater protection than that achieved with 1 nM bafilomycin A1 (Fig. 10, a and b). Conversely, Bax deficiency prevented the reduction in viability and increase in caspase-3-like activity that was induced by treatment for 24 h with 10 nM bafilomycin A1 (Fig. 10, c and d). The effects of targeted deletion of Bax on the activity of caspase-3 were confirmed via Western blot (Fig. 10e). Furthermore, Western blot analysis indicated that Bax deficiency did not prevent the chloroquine-induced increase in LC3-II (Fig. 10e).


Figure 10
View larger version (32K):
[in this window]
[in a new window]
 
Fig. 10. The cytoprotective effects of bafilomycin A1 (BafA1) are Bax-independent. Control (CTL)- and chloroquine (CQ; 20 µM)-treated, wild-type (WT) and Bax-deficient (KO) CGNs were assessed for viability (a and c) and fractional caspase-3-like activity (b and d) in the presence of 1 nM (a and b) or 10 nM (c and d) BafA1. At least three independent experiments of at least three replicates represent each concentration and genotype tested. Representative Western blot (e) indicates cleaved caspase-3 and processing of LC3 in WT and KO lysates after 24-h treatment with CTL or CQ. NT, no treatment; 0 h. For a and b, significant effects of genotype versus treatment were assessed via two-factor ANOVA and Bonferroni's post hoc test and significant treatment effects were assessed via one-factor ANOVA and Bonferroni's post hoc test; p < 0.05 (a, compared with respective WT treatment pair; b, compared with genotype-matched CTL; c, compared with genotype-matched treatment with 1 nM BafA1; d, compared with genotype-matched treatment with CQ). For c and d, significant effects of genotype versus treatment were assessed via two-factor ANOVA and Bonferroni's post hoc test and significant treatment effects were assessed via unpaired, two-tailed t test; p < 0.05 (a, compared with respective WT treatment pair; {dagger}, compared with genotype-matched CTL).

 
Because chloroquine induced a dramatic increase in the activity of caspase-3, cultures of CGNs were prepared from caspase-3-deficient mice to determine the relative positioning of this effector caspase in the pathway of cell death induced by chloroquine. The absence of caspase-3 did not prevent the chloroquine-induced decrease in viability (Fig. 11a), although a significant attenuation in caspase-3-like activity was observed (Fig. 11b). To determine whether other caspases (e.g., caspase-9) may be critical for chloroquine-induced death, CGNs were treated with BOC-aspartyl(OMe)-fluoromethyl ketone, a broad-spectrum caspase inhibitor. Treatment with this inhibitor did not attenuate chloroquine-induced death (Fig. 11c) but did significantly attenuate the chloroquine-induced increase in caspase-3-like activity (Fig. 11d).


Figure 11
View larger version (10K):
[in this window]
[in a new window]
 
Fig. 11. Neither caspase-3 deficiency nor pharmacological inhibition of caspases prevents chloroquine-induced death. Cell viability (a and c) and fractional caspase-3-like activity (b and d) were measured 24 h after treatment with chloroquine (CQ) or control (CTL) in wild type (WT) and caspase-3-deficient (KO) CGNs (a and b) or in CGNs cotreated with the broad spectrum caspase inhibitor BOC-aspartyl(Ome)-fluoromethyl ketone (BAF, 150 µM; c and d). At least three independent experiments of at least three replicates represent each concentration and genotype tested. For a and b, significant effects of genotype were assessed via two-tailed, unpaired t test; p < 0.05 (*, compared with CTL). For c and d, significant effects of treatment were assessed via one-factor ANOVA and Bonferroni's post hoc test; p < 0.05 (*, compared with CTL; {dagger}, compared with CQ).

 
Discussion

Inhibition of autophagy by chloroquine or bafilomycin A1 occurs via a disruption in the pH of acidic vesicles, which prevents the fusion of autophagosomes with lysosomes and thus increases the cellular burden of autophagosomes and has been shown to precede and possibly induce Bax- and mitochondrial-dependent apoptosis (Zaidi et al., 2001Go; Boya et al., 2003Go, 2005Go). In the present study, chloroquine produced a concentration- and time-dependent increase in caspase-3-like enzymatic activity and decrease in the viability of CGNs (Figs. 1 and 2). The chloroquine-induced death of CGNs was due to the engagement of the intrinsic apoptotic pathway, as evidenced by a Bax-dependent increase in caspase-3 activity and decrease in cell viability (Fig. 10). Chloroquine also induced a dramatic increase in LC3-II (Figs. 2 and 6) that preceded activation of caspase-3 (Fig. 2) and was Bax-independent (Fig. 10). In addition, treatment with ≥10 nM bafilomycin A1 increased levels of LC3-II (Fig. 4) and caused an accumulation of vacuoles (Fig. 8), enhanced Bax-dependent apoptosis (Figs. 3, 4, and 10) and severely impaired vacuolar acidification (Fig. 7), results that are similar to those of previous studies (Boya et al., 2003Go, 2005Go). It is noteworthy that results of the present study confirm and extend previous studies suggesting that an alteration in autophagy precedes and initiates apoptotic cell death (Lee and Baehrecke, 2001Go; Boya et al., 2003Go, 2005Go; Martin and Baehrecke, 2004Go; Gonzalez-Polo et al., 2005Go).

Cotreatment with bafilomycin A1 dramatically and significantly attenuated chloroquine-induced apoptosis (Figs. 5 and 6), an effect that was characterized by an inverted, U-shaped concentration-dependence. This effect was maximal at a concentration of bafilomycin A1 (0.3–1 nM) that by itself neither altered vacuolar acidification (Fig. 7) nor induced the formation of autophagosomes (Fig. 4). This concentration of bafilomycin A1 was shown previously to have minimal inhibitory effect on V-ATPase in a cell-free system (Bowman et al., 1988Go; Drose et al., 1993Go). However, 10 to 100 nM bafilomycin A1 still inhibited chloroquine-induced death, albeit not as robustly as with lower concentrations, which is probably due to bafilomycin A1-dependent induction of the intrinsic apoptotic pathway at ≥10 nM. It is possible that high concentrations of bafilomycin A1 prevent a distinct, caspase-independent pathway of chloroquine-induced cell death, because chloroquine-induced caspase-3-like activity was not affected by ≥10 nM bafilomycin A1. Nevertheless, 100 nM bafilomycin A1 has been shown previously to inhibit chloroquine-induced apoptosis of HeLa cells (Boya et al., 2003Go), which suggests cell-type-specific effects of bafilomycin A1 and chloroquine. Effects of bafilomycin A1 in various cell culture models have been typically reported using concentrations ≥10 nM (Boya et al., 2003Go, 2005Go; Kanzawa et al., 2003Go, 2004Go). Together, our results reveal a novel, concentration-dependent dichotomy of bafilomycin A1 function such that ≤1 nM bafilomycin A1 inhibits chloroquine-induced apoptosis apart from its inhibition of vacuolar acidification. In addition, the protective effects of bafilomycin A1 may be limited to stimuli that induce alterations in autophagy, because it did not prevent death caused by staurosporine, a protein kinase inhibitor and classic apoptosis-inducing agent (Fig. 5).

In the present study, CGNs that survived the 24 h chloroquine incubation stained intensely for LysoTracker Red. A chloroquine-induced increase in LysoTracker Red staining intensity has been documented previously in other cell types (Boya et al., 2003Go, 2005Go) and occurs concomitantly with an increase in autophagosome number yet dissipates only in cells exhibiting a subsequent disruption in mitochondrial membrane potential and resultant apoptosis (Boya et al., 2005Go). Thus, the CGNs staining intensely with LysoTracker Red probably represent the viable population of neurons that have intact mitochondrial function, although mitochondrial function was not directly measured in the present study. Although LysoTracker Red does not discriminate among different types of acidic vesicles or organelles, its staining pattern may represent a population of late or mature autophagosomes, as suggested by ultrastructural analysis (Fig. 8), that become increasingly acidic during their maturation (Dunn, 1990Go; Punnonen et al., 1992Go). By disrupting the function of lysosomes, chloroquine may prevent their fusion with late autophagosomes, resulting ultimately in the accumulation of late autophagosomes.

One nanomolar bafilomycin A1 increased not only the population of CGNs that survived the chloroquine insult but also the number of viable CGNs with intensely stained, LysoTracker Red-positive acidic vesicles (Fig. 7). A relative lack of apoptotic nuclei was seen ultrastructurally after treatment for 24 h with chloroquine plus 0.3 nM bafilomycin A1 (Fig. 8), confirming the results of caspase activity assays (Fig. 5) and Western blot analysis (Fig. 6). In addition, ultrastructural analysis suggests that there is little if any effect of 0.3 nM bafilomycin A1 on the chloroquine-induced accumulation of autophagosomes. Together, these data suggest that bafilomycin A1, at concentrations below its ability to inhibit V-ATPase, may prevent not only the de-stabilization of acidic vesicles (as evidenced by even greater numbers of viable cells exhibiting intense LysoTracker Red staining) but also the disruption of mitochondrial function that would lead to induction of the intrinsic apoptotic pathway.

Conversely, treatment with 10 nM bafilomycin A1 completely prevented LysoTracker Red staining, both in the presence or absence of chloroquine. This may suggest that bafilomycin A1 (via inhibition of V-ATPase) prevents the fusion and maturation of early autophagosomes, as described previously (Yamamoto et al., 1998Go), thus accumulating a population of autophagosomes with a pH too high for detection with LysoTracker Red. Ultrastructural analysis indeed confirmed the accumulation of single membraned, cytoplasmic vacuoles in CGNs treated with 10 nM bafilomycin A1 that appeared much larger and swollen compared with those in cells treated with chloroquine or chloroquine plus 0.3 nM bafilomycin A1 (Fig. 8) and were not whorled in appearance, which may indicate a population of mature autophagosomes whose fusion with lysosomes was prevented. LC3-II has been documented in both early and late autophagosomes (Jager et al., 2004Go), which would indicate why both chloroquine and 10 nM bafilomycin A1 increased levels of LC3-II yet produced differential staining patterns with LysoTracker Red and differential vacuolar morphology.

Bafilomycin A1 attenuated the chloroquine-induced increase in the ratio of LC3-II/LC3-I (Fig. 6). However, these changes were due primarily to increased levels of cytosolic LC3-I with little change in levels of LC3-II (Fig. 6). Results of ultrastructural analyses (Fig. 8) do not suggest a decreased accumulation in autophagosomes upon cotreatment with chloroquine and bafilomycin A1. A possible interpretation of these results would be that bafilomycin A1, especially at low concentrations (≤ 1 nM) either induces autophagy as a survival response to chloroquine or attenuates the chloroquine-induced inhibition of autophagy. An increase in levels of LC3-II has been reported from both the induction and inhibition of autophagy (Tanida et al., 2005Go), which could explain why ≤1 nM bafilomycin A1 did not decrease levels of LC3-II. However, neither 1 nor 10 nM bafilomycin A1 prevented the chloroquine-induced inhibition of autophagy (Fig. 9), which suggests that bafilomycin A1 does not prevent chloroquine-induced death by altering autophagosome formation and/or recycling.

Although our results clearly indicate that chloroquine-induced death is in part Bax-dependent, the degree of protection afforded by 1 nM bafilomycin A1 against chloroquine was substantially greater than that provided by Bax deficiency. Considering that bafilomycin A1 significantly attenuates activation of caspase-3, we propose that the putative protective mechanism of bafilomycin A1 lies upstream of Bax and may prevent activation of the intrinsic apoptotic pathway (Fig. 12). Because Bax deficiency virtually prevented the chloroquine-induced activation of caspase-3 (Fig. 10), this additional protective effect of bafilomycin A1 cannot be attributed to its functional inhibition of molecules such as Bak, which shares redundant regulatory functions with Bax (Wei et al., 2001Go; Putcha et al., 2002Go). In contrast, Bax deficiency significantly attenuated the induction of caspase-3-like activity and the reduction in viability resulting from 10 nM bafilomycin A1 (Fig. 10), which suggests that similar to the effects of chloroquine, the inhibition of autophagy by high concentrations of bafilomycin A1 induces Bax-dependent apoptosis.


Figure 12
View larger version (22K):
[in this window]
[in a new window]
 
Fig. 12. Proposed model indicates concentration-dependent effects of bafilomycin A1 (BafA1) on chloroquine-induced apoptosis. At low concentrations, BafA1 inhibits chloroquine-induced apoptosis, either upstream of or at the level of Bax. High concentrations of BafA1 do not prevent chloroquine-dependent apoptosis and, in the absence of chloroquine, seem to inhibit autophagy and induce Bax-dependent apoptosis.

 

Although chloroquine induced a robust activation of caspase-3 (Figs. 1, 2, 5, 6, and 10), the targeted deletion of caspase-3 and broad pharmacological inhibition of caspases did not prevent chloroquine-induced death (Fig. 11). Similar results were obtained previously from our laboratory with cultured telencephalic neurons (Zaidi et al., 2001Go), which suggests that the commitment point for chloroquine-induced neuron death lies upstream of caspase activation. These findings are in contrast to the chloroquine-induced death of HeLa cells, which was attenuated upon treatment with a general caspase inhibitor (Boya et al., 2003Go). Activation of the intrinsic apoptotic pathway in chloroquine-induced neuron death is clear, considering that the temporal and concentration-dependent, chloroquine-induced decrease in viability closely follows the pattern of caspase-3 activity and that 1 nM bafilomycin A1 dramatically attenuates activation of caspase-3 concomitant with decreased cell death. This conclusion is further supported by the observed decrease in caspase-3 activity and cell death in the absence of Bax. Together, the results of this study suggest that the commitment point of chloroquine-induced neuron death lies upstream of caspase activation (Fig. 12) at the level of Bax, and that the protective effects of bafilomycin A1 lie upstream of Bax.

Chloroquine-induced neurotoxicity has been documented in humans (James, 1988Go; Phillips-Howard and ter Kuile, 1995Go; Telgt et al., 2005Go) and has been linked to cerebellar ataxia (James, 1988Go). Animal models of chloroquine treatment have indicated the cerebellar accumulation of lipoprotein (Fischer and Nelson, 1974Go; Ivy et al., 1989Go), which suggests that chloroquine is an in vivo inhibitor of neuronal autophagy. Studies assessing the in vivo effects of bafilomycins are limited in number (Myers et al., 2001Go; Hettiarachchi et al., 2004Go), and the ability of bafilomycins to cross the blood-brain barrier is unknown, thus warranting future pharmacokinetic analysis. In vitro analysis of CGNs has shown a bafilomycin A1-induced inhibition of glutamate release (Cousin et al., 1995Go), and bafilomycin A1 reportedly inhibits the vesicular uptake of many neurotransmitters, including but not limited to glutamate, serotonin, and GABA (Moriyama and Futai, 1990Go; Roseth et al., 1995Go). It is unlikely that the protective effects of bafilomycin A1 are due to alterations in neurotransmitter uptake/release, because these actions are observed at micromolar concentrations and 1 nM bafilomycin A1, its most effective neuroprotective concentration, does not inhibit glutamate uptake (Roseth et al., 1995Go). Finally it is worth noting that lysosomal dysfunction has been implicated in a variety of neurodegenerative conditions including Alzheimer's, Parkinson's, and Huntington's diseases (Bahr and Bendiske, 2002Go). Whether bafilomycin A1 has neuroprotective action in any of these conditions requires further investigation.

Acknowledgements

We thank Rizwan S. Akhtar, Ying Geng, and Jayne M. Ness for critical reading of the manuscript, and to Rizwan S. Akhtar for expert assistance in preparation of the manuscript.

Footnotes

This work was supported by National Institute of Neurological Disorders and Stroke grant NS35107 (to K.A.R.), National Institute of Diabetes and Digestive and Kidney Diseases grant DK19645 and National Institute on Aging grant AG10299 (to R.E.S.), and an award from the Batten Disease Support and Research Association (to J.J.S.).

Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.

doi:10.1124/mol.105.018408.

ABBREVIATIONS: LC3, microtubule-associated protein light chain-3; V-ATPase, vacuolar type ATPase; CGN, cerebellar granule neuron; PBS, phosphate-buffered saline; ANOVA, analysis of variance.

Address correspondence to: Dr. Kevin A. Roth, Department of Pathology, Division of Neuropathology, University of Alabama at Birmingham, SC961, 1530 3rd Ave South, Birmingham, AL 35294-0017. E-mail: kroth{at}path.uab.edu

References

Bahr BA and Bendiske J (2002) The neuropathogenic contributions of lysosomal dysfunction. J Neurochem 83: 481-489.[CrossRef][Medline]

Baird JK (2005) Effectiveness of antimalarial drugs. N Engl J Med 352: 1565-1577.[Free Full Text]

Bowman EJ, Siebers A, and Altendorf K (1988) Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells and plant cells. Proc Natl Acad Sci USA 85: 7972-7976.[Abstract/Free Full Text]

Boya P, Gonzalez-Polo RA, Casares N, Perfettini JL, Dessen P, Larochette N, Metivier D, Meley D, Souquere S, Yoshimori T, et al. (2005) Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol 25: 1025-1040.[Abstract/Free Full Text]

Boya P, Gonzalez-Polo RA, Poncet D, Andreau K, Vieira HL, Roumier T, Perfettini JL, and Kroemer G (2003) Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. Oncogene 22: 3927-3936.[CrossRef][Medline]

Bredesen DE (2000) Apoptosis: overview and signal transduction pathways. J Neurotrauma 17: 801-810.[Medline]

Clarke PG (1990) Developmental cell death: morphological diversity and multiple mechanisms. Anat Embryol (Berl) 181: 195-213.[Medline]

Cousin MA, Nicholls DG, and Pocock JM (1995) Modulation of ion gradients and glutamate release in cultured cerebellar granule cells by ouabain. J Neurochem 64: 2097-2104.[Medline]

de Duve C, de Barsy T, Poole B, Trouet A, Tulkens P, and Van Hoof F (1974) Commentary. Lysosomotropic agents. Biochem Pharmacol 23: 2495-2531.[CrossRef][Medline]

Drose S, Bindseil KU, Bowman EJ, Siebers A, Zeeck A, and Altendorf K (1993) Inhibitory effect of modified bafilomycins and concanamycins on P- and V-type adenosinetriphosphatases. Biochemistry 32: 3902-3906.[CrossRef][Medline]

Dunn WA Jr (1990) Studies on the mechanisms of autophagy: maturation of the autophagic vacuole. J Cell Biol 110: 1935-1945.[Abstract/Free Full Text]

Eskelinen E-L (2005) Maturation of autophagic vacuoles in mammalian cells. Autophagy 1: 1-10.[Medline]

Fischer VW and Nelson JS (1974) Chloroquine-enhanced cerebellovascular changes in nutritionally imbalanced chicks. Acta Neuropathol (Berl) 29: 65-72.[CrossRef][Medline]

Gonzalez-Polo RA, Boya P, Pauleau AL, Jalil A, Larochette N, Souquere S, Eskelinen EL, Pierron G, Saftig P, and Kroemer G (2005) The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death. J Cell Sci 118: 3091-3102.[Abstract/Free Full Text]

Hettiarachchi KD, Zimmet PZ, and Myers MA (2004) Transplacental exposure to bafilomycin disrupts pancreatic islet organogenesis and accelerates diabetes onset in NOD mice. J Autoimmun 22: 287-296.[CrossRef][Medline]

Ichimura Y, Kirisako T, Takao T, Satomi Y, Shimonishi Y, Ishihara N, Mizushima N, Tanida I, Kominami E, Ohsumi M, et al. (2000) A ubiquitin-like system mediates protein lipidation. Nature (Lond) 408: 488-492.[CrossRef][Medline]

Issa SN and Ruderman EM (2004) Damage control in rheumatoid arthritis. Hardhitting, early treatment is crucial to curbing joint destruction. Postgrad Med 116: 14.[Medline]

Ivy GO, Kanai S, Ohta M, Smith G, Sato Y, Kobayashi M, and Kitani K (1989) Lipofuscin-like substances accumulate rapidly in brain, retina and internal organs with cysteine protease inhibition. Adv Exp Med Biol 266: 31-45.[Medline]

Jager S, Bucci C, Tanida I, Ueno T, Kominami E, Saftig P, and Eskelinen EL (2004) Role for Rab7 in maturation of late autophagic vacuoles. J Cell Sci 117: 4837-4848.[Abstract/Free Full Text]

James RF (1988) Cerebellar ataxia in patients with malaria treated with chloroquine. Postgrad Med J 64: 16719.

Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, and Yoshimori T (2000) LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO (Eur Mol Biol Organ) J 19: 5720-5728.[CrossRef][Medline]

Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, and Kondo S (2004) Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 11: 448-457.[CrossRef][Medline]

Kanzawa T, Kondo Y, Ito H, Kondo S, and Germano I (2003) Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res 63: 2103-2108.[Abstract/Free Full Text]

Kinoshita K, Waritani T, Noto M, Takizawa K, Minemoto Y, Nishikawa A, and Ohkuma S (1996) Bafilomycin A1 induces apoptosis in PC12 cells independently of intracellular PH. FEBS Lett 398: 61-66.[CrossRef][Medline]

Klionsky DJ and Emr SD (2000) Autophagy as a regulated pathway of cellular degradation. Science (Wash DC) 290: 1717-1721.[Abstract/Free Full Text]

Knudson CM, Tung KS, Tourtellotte WG, Brown GA, and Korsmeyer SJ (1995) Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science (Wash DC) 270: 96-99.[Abstract/Free Full Text]

Kuida K, Zheng TS, Na S, Kuan C, Yang D, Karasuyama H, Rakic P, and Flavell RA (1996) Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature (Lond) 384: 368-372.[CrossRef][Medline]

Lai JH, Ho LJ, Lu KC, Chang DM, Shaio MF, and Han SH (2001) Western and Chinese antirheumatic drug-induced T cell apoptotic DNA damage uses different caspase cascades and is independent of Fas/Fas ligand interaction. J Immunol 166: 6914-6924.[Abstract/Free Full Text]

Lee CY and Baehrecke EH (2001) Steroid regulation of autophagic programmed cell death during development. Development 128: 1443-1455.[Abstract]

Lum JJ, Bauer DE, Kong M, Harris MH, Li C, Lindsten T, and Thompson CB (2005a) Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 120: 237-248.[CrossRef][Medline]

Lum JJ, DeBerardinis RJ, and Thompson CB (2005b) Autophagy in metazoans: cell survival in the land of plenty. Nat Rev Mol Cell Biol 6: 439-448.[CrossRef][Medline]

Martin DN and Baehrecke EH (2004) Caspases function in autophagic programmed cell death in Drosophila. Development 131: 275-284.[Abstract/Free Full Text]

Moriyama Y and Futai M (1990) H+-ATPase, a primary pump for accumulation of neurotransmitters, is a major constituent of brain synaptic vesicles. Biochem Biophys Res Commun 173: 443-448.[CrossRef][Medline]

Myers MA, Mackay IR, Rowley MJ, and Zimmet PZ (2001) Dietary microbial toxins and type 1 diabetes–a new meaning for seed and soil. Diabetologia 44: 1199-1200.[CrossRef][Medline]

Nishihara T, Akifusa S, Koseki T, Kato S, Muro M, and Hanada N (1995) Specific inhibitors of vacuolar type H+-ATPases induce apoptotic cell death. Biochem Biophys Res Commun 212: 255-262.[CrossRef][Medline]

Nowoslawski L, Klocke BJ, and Roth KA (2005) Molecular regulation of acute ethanol-induced neuron apoptosis. J Neuropathol Exp Neurol 64: 490-497.[Medline]

Pattingre S, Petiot A, and Codogno P (2004) Analyses of Galpha-interacting protein and activator of G-protein-signaling-3 functions in macroautophagy. Methods Enzymol 390: 17-31.[Medline]

Phillips-Howard PA and ter Kuile FO (1995) CNS adverse events associated with antimalarial agents. Fact or fiction? Drug Saf 12: 370-383.[Medline]

Punnonen EL, Autio S, Marjomaki VS, and Reunanen H (1992) Autophagy, cathepsin L transport and acidification in cultured rat fibroblasts. J Histochem Cytochem 40: 1579-1587.[Abstract]

Putcha GV, Harris CA, Moulder KL, Easton RM, Thompson CB, and Johnson EM Jr (2002) Intrinsic and extrinsic pathway signaling during neuronal apoptosis: lessons from the analysis of mutant mice. J Cell Biol 157: 441-453.[Abstract/Free Full Text]

Roseth S, Fykse EM, and Fonnum F (1995) Uptake of L-glutamate into rat brain synaptic vesicles: effect of inhibitors that bind specifically to the glutamate transporter. J Neurochem 65: 96-103.[Medline]

Schweichel JU and Merker HJ (1973) The morphology of various types of cell death in prenatal tissues. Teratology 7: 253-266.[CrossRef][Medline]

Seglen PO and Gordon PB (1980) Effects of lysosomotropic monoamines, diamines, amino alcohols and other amino compounds on protein degradation and protein synthesis in isolated rat hepatocytes. Mol Pharmacol 18: 468-475.[Abstract/Free Full Text]

Shacka JJ and Roth KA (2005) Regulation of neuronal cell death and neurodegeneration by members of the Bcl-2 family: therapeutic implications. Curr Drug Targets CNS Neurol Disord 4: 25-39.[CrossRef][Medline]

Shindler KS, Latham CB, and Roth KA (1997) Bax deficiency prevents the increased cell death of immature neurons in Bcl-x-deficient mice. J Neurosci 17: 3112-3119.[Abstract/Free Full Text]

Tanida I, Minematsu-Ikeguchi N, Ueno T, and Kominami E (2005) Lysosomal turnover, but not a cellular level, of endogenous LC3 is a marker for autophagy. Autophagy 1: 84-91.[Medline]

Telgt DS, van der Ven AJ, Schimmer B, Droogleever-Fortuyn HA, and Sauerwein RW (2005) Serious psychiatric symptoms after chloroquine treatment following experimental malaria infection. Ann Pharmacother 39: 551-554.[Abstract/Free Full Text]

Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB, and Korsmeyer SJ (2001) Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science (Wash DC) 292: 727-730.[Abstract/Free Full Text]

Wozniacka A and McCauliffe DP (2005) Optimal use of antimalarials in treating cutaneous lupus erythematosus. Am J Clin Dermatol 6: 1-11.[Free Full Text]

Yamamoto A, Tagawa Y, Yoshimori T, Moriyama Y, Masaki R, and Tashiro Y (1998) Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct Funct 23: 33-42.[Medline]

Yoshimori T, Yamamoto A, Moriyama Y, Futai M, and Tashiro Y (1991) Bafilomycin A1, a specific inhibitor of vacuolar-type H+-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J Biol Chem 266: 17707-17712.[Abstract/Free Full Text]

Zaidi AU, McDonough JS, Klocke BJ, Latham CB, Korsmeyer SJ, Flavell RA, Schmidt RE, and Roth KA (2001) Chloroquine-induced neuronal cell death is P53 and Bcl-2 family-dependent but caspase-independent. J Neuropathol Exp Neurol 60: 937-945.[Medline]




This article has been cited by other articles:


Home page
J. Neurosci.Home page
J. J. Shacka, B. J. Klocke, C. Young, M. Shibata, J. W. Olney, Y. Uchiyama, P. Saftig, and K. A. Roth
Cathepsin D Deficiency Induces Persistent Neurodegeneration in the Absence of Bax-Dependent Apoptosis
J. Neurosci., February 21, 2007; 27(8): 2081 - 2090.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
J.-h. Zhu, C. Horbinski, F. Guo, S. Watkins, Y. Uchiyama, and C. T. Chu
Regulation of Autophagy by Extracellular Signal-Regulated Protein Kinases During 1-Methyl-4-Phenylpyridinium-Induced Cell Death
Am. J. Pathol., January 1, 2007; 170(1): 75 - 86.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.018408v1
69/4/1125    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shacka, J. J.
Right arrow Articles by Roth, K. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shacka, J. J.
Right arrow Articles by Roth, K. A.


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics